Free Trial

89bio (ETNB) Competitors

89bio logo
$7.98 -0.01 (-0.13%)
(As of 11/20/2024 ET)

ETNB vs. ICPT, ALBO, ARWR, MLTX, AGIO, VRNA, PTCT, DYN, BHC, and EWTX

Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Intercept Pharmaceuticals (ICPT), Albireo Pharma (ALBO), Arrowhead Pharmaceuticals (ARWR), MoonLake Immunotherapeutics (MLTX), Agios Pharmaceuticals (AGIO), Verona Pharma (VRNA), PTC Therapeutics (PTCT), Dyne Therapeutics (DYN), Bausch Health Companies (BHC), and Edgewise Therapeutics (EWTX). These companies are all part of the "medical" sector.

89bio vs.

89bio (NASDAQ:ETNB) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.

In the previous week, 89bio had 10 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 10 mentions for 89bio and 0 mentions for Intercept Pharmaceuticals. Intercept Pharmaceuticals' average media sentiment score of 0.30 beat 89bio's score of -0.17 indicating that Intercept Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
89bio Neutral
Intercept Pharmaceuticals Neutral

Intercept Pharmaceuticals received 959 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 71.26% of users gave Intercept Pharmaceuticals an outperform vote while only 64.46% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
89bioOutperform Votes
107
64.46%
Underperform Votes
59
35.54%
Intercept PharmaceuticalsOutperform Votes
1066
71.26%
Underperform Votes
430
28.74%

83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 2.8% of 89bio shares are owned by company insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

89bio currently has a consensus price target of $30.33, suggesting a potential upside of 280.12%. Given 89bio's stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Intercept Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89bio
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.86
Intercept Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

89bio has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

89bio has a net margin of 0.00% compared to Intercept Pharmaceuticals' net margin of -19.39%. 89bio's return on equity of -59.58% beat Intercept Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
89bioN/A -59.58% -52.21%
Intercept Pharmaceuticals -19.39%-77.48%-11.99%

Intercept Pharmaceuticals has higher revenue and earnings than 89bio. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A-$142.19M-$2.91-2.74
Intercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84

Summary

89bio and Intercept Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETNB vs. The Competition

Metric89bioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$847.95M$6.48B$5.07B$8.89B
Dividend YieldN/A8.11%4.99%4.07%
P/E Ratio-2.744.4283.5712.93
Price / SalesN/A375.031,220.3088.33
Price / CashN/A52.5939.4636.25
Price / Book2.2410.126.936.25
Net Income-$142.19M$153.61M$119.12M$225.93M
7 Day Performance-8.80%-2.00%-1.83%-1.32%
1 Month Performance-1.85%-7.47%-3.64%0.60%
1 Year Performance5.14%31.80%31.64%26.23%

89bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETNB
89bio
1.4925 of 5 stars
$7.98
-0.1%
$30.33
+280.1%
+3.1%$847.95MN/A-2.7440
ICPT
Intercept Pharmaceuticals
N/A$19.00
flat
N/AN/A$794.77M$285.71M-12.84341
ALBO
Albireo Pharma
N/A$44.15
-0.2%
N/A+0.0%$913.91M$40.58M-6.57130Analyst Forecast
ARWR
Arrowhead Pharmaceuticals
3.5698 of 5 stars
$18.71
+0.6%
$45.33
+142.3%
-35.3%$2.31B$240.74M0.00400Upcoming Earnings
Analyst Forecast
MLTX
MoonLake Immunotherapeutics
3.2689 of 5 stars
$49.82
+1.0%
$79.00
+58.6%
+16.8%$3.15BN/A0.002
AGIO
Agios Pharmaceuticals
3.3124 of 5 stars
$54.62
+0.4%
$52.33
-4.2%
+154.0%$3.10B$26.82M4.81390
VRNA
Verona Pharma
2.6734 of 5 stars
$38.85
+2.0%
$43.83
+12.8%
+163.7%$3.04B$460,000.00-20.2330Positive News
PTCT
PTC Therapeutics
2.5495 of 5 stars
$41.96
+6.6%
$42.00
+0.1%
+89.3%$3.04B$937.82M0.001,410Analyst Downgrade
DYN
Dyne Therapeutics
3.3831 of 5 stars
$29.99
+1.0%
$51.40
+71.4%
+181.6%$3.02BN/A0.00100Insider Trade
Analyst Revision
BHC
Bausch Health Companies
3.4347 of 5 stars
$8.20
+0.1%
$7.75
-5.4%
+16.3%$3.01B$8.76B0.0020,270Positive News
EWTX
Edgewise Therapeutics
1.7269 of 5 stars
$31.95
+1.4%
$38.40
+20.2%
+396.9%$2.98BN/A0.0060

Related Companies and Tools


This page (NASDAQ:ETNB) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners